Skip to content

    Balaji Amines

    BALAMINES
    Chemicals·18 May 2026
    Management Summary

    Balaji Amines reported a strong Q4 FY26 with significant revenue and profit growth, driven by improved margins and operational efficiencies. The company made substantial progress on its strategic expansion projects, including DME, NMM, ACN, and Balaji Specialty Chemicals, which are expected to drive future growth. Despite challenges like geopolitical impacts and raw material volatility, management expressed confidence in maintaining profitability and achieving volume growth targets.

    Highlights

    7

    • Consolidated revenue for Q4 FY26 stood at INR 403 crores, registering a 12% YoY growth compared to INR 361 crores in Q4 FY25.

    • Consolidated EBITDA for Q4 FY26 was INR 102 crores, a significant increase from INR 68 crores in Q4 FY25.

    • EBITDA margin improved to 25% in Q4 FY26, up from 19% in Q4 FY25 and 18% in Q3 FY26, driven by better operating leverage, stable raw material conditions, and favorable product mix.

    • Profit after-tax for Q4 FY26 stood at INR 65 crores, a 62.5% YoY increase from INR 40 crores in Q4 FY25.

    • Diluted EPS for Q4 FY26 was INR 19.99 per equity share, compared to INR 9.49 per equity share in Q3 FY26.

    • The company maintained a strong consolidated net worth of INR 2,152 crores as of March 2026.

    • DME plant at Unit 4 is expected to be commissioned during Q1 FY27, NMM during FY27, and ACN during Q2 FY27, with Balaji Specialty Chemicals Unit-I in H1 FY27 and Unit-II in Q4 FY27.

    Concerns

    4

    • Production was briefly impacted in March 2026 due to an external geopolitical situation.

    • Some plants (DMF, butylamines, battery chemicals) are operating at low utilization (35-40%) due to market conditions and nascent demand.

    • Raw material prices, such as Monoethanolamine, have increased significantly, sometimes up to 3 times the normal price.

    • Transportation approval for Dimethyl Ether (DME) is still pending, though manufacturing approval is in place.

    Key financials

    Metrics

    6

    Periods

    2

    Headline

    5
    • Consolidated Revenue
      ₹403 Cr
      YoY+11.6%
    • Consolidated EBITDA
      ₹102 Cr
      YoY+50%
    • Consolidated EBITDA Margin
      25%
    • Consolidated PAT
      ₹65 Cr
      YoY+62.5%QoQ+109.7%
    • Diluted EPS
      ₹19.99
      QoQ+110.6%

    FY26

    1
    • Net Cash from Operating Activities
      ₹184 Cr

    Segment breakdown

    • Amines7,746 metric tons28.3%
    • Amines Derivatives8,935 metric tons32.7%
    • Specialty Chemicals10,660 metric tons39.0%
    Donut· Share of Sales Volume

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹275 crores

    Debt

    Debt disclosed

    Guidance & targets

    12
    CategoryTargetPriority
    Volume
    Volume Growth
    25-30%
    		High
    Volume
    DME Utilization (Current FY)
    30-40%
    		Medium
    Volume
    DME Utilization (End of Current FY)
    50-60%
    		Medium
    Volume
    DME Utilization (Coming Years)
    80-90%
    		Medium
    Volume
    Consolidated Volume Growth
    10-15%
    		Medium
    Profitability
    EBITDA Margin
    22-23%
    		High
    Revenue
    Revenue
    INR 3,000 crores
    		High
    Capacity
    DME Plant Commissioning
    Q1 FY27
    		High
    Capacity
    NMM Project Commissioning
    FY27
    		High
    Capacity
    ACN Plant Commissioning
    Q2 FY27
    		High
    Capacity
    Balaji Specialty Chemicals Unit-I (EDA-based) Commissioning
    H1 FY27
    		High
    Capacity
    Balaji Specialty Chemicals Unit-II (HCN, NaCN, EDTA) Commissioning
    Q4 FY27
    		High

    DME Plant Commissioning & Transportation Approval

    Q1 FY27 (commissioning), within a month (transportation approval)
    CurrentPlant constructed, commissioning ongoing, transportation approval pending
    TargetCommercial operations commence, transportation approval secured

    Why it matters

    Crucial for realizing revenue from the new DME plant and achieving utilization targets.

    The dimethyl ether, our DME plant at Unit 4 is expected to be commissioned during the first quarter of FY27... Only thing is for the transportation part of the approvals, have already been on the place. So, that is a reason we are going ahead. Plant is already fully constructed. Just commissioning is going on. Now, the commissioning activities are going on.

    How to verify

    guidance_and_targets[category='Capacity'][metric='DME Plant Commissioning']

    Risks & concerns

    5
    RiskSeverity

    Geopolitical situation impacting production

    Production was briefly impacted in March 2026 due to an external geopolitical situation, but managed through inventory planning. — Management acknowledged

    medium

    Raw material price volatility and increases

    Raw material prices, like Monoethanolamine, have increased up to 3 times normal, requiring alert inventory management. — Management acknowledged

    high

    Low utilization for certain plants

    DMF, butylamines, and battery chemicals plants are operating at 35-40% utilization due to market conditions and nascent demand for battery chemicals. — Management acknowledged

    medium

    DME transportation approval pending

    While manufacturing approval for DME is in place, transportation approval is still pending, which is crucial for bulk sales. — Management acknowledged

    medium

    Teething problems for new products

    New products like DME, NMM, and ACN may face initial challenges in meeting customer specifications and gaining market acquaintance. — Management acknowledged

    medium

    Q&A highlights

    7

    “See, the new projects, they are not the same products, increasing the capacity. They are all new products like we are talking of the Dimethyl Ether, which is an alternate to the LPG. So this we planned about 4, 5 years back by contacting the NITI Aayog. That product will be commissioning probably maybe in this month only. And other thing is Acetonitrile which was that was the old technology. We have just improved the technology. And you are talking about the utilization, yes, only 1 or 2 plants are utilized very lower capacity like DMF and like butylamines, like battery chemicals, DMC and all because the battery manufacturers are yet to take off so there's a reason those clients. So we are gearing up. And we are getting ready for the tomorrow's requirements.”

    Clarifies that new expansions are for different products and low utilization in some existing plants is due to market conditions for those specific products, not overcapacity across the board.

    asked by Priyank Chheda

    2 min read6 chapters

    Detailed Narrative

    01

    Q4 FY26 Performance Highlights

    Balaji Amines delivered a robust Q4 FY26, with consolidated revenue growing 12% year-on-year to INR 403 crores. EBITDA saw a significant increase to INR 102 crores, leading to an expanded EBITDA margin of 25%, up from 19% in Q4 FY25. Profit after-tax surged by 62.5% YoY to INR 65 crores, and diluted EPS reached INR 19.99, reflecting strong operational performance and favorable product mix.

    02

    FY26 Annual Performance and Financial Strength

    For the full fiscal year 2026, consolidated revenue stood at INR 1,454 crores, a slight increase from INR 1,430 crores in FY25. EBITDA grew 11% to INR 294 crores, with the margin improving to 20% from 19% in FY25. The company maintained a strong balance sheet with consolidated net worth at INR 2,152 crores and manageable debt of INR 133 crores, primarily for ongoing expansion projects.

    03

    Strategic Projects and Capacity Expansion

    Balaji Amines is actively pursuing several strategic projects. The Dimethyl Ether (DME) plant at Unit 4 is expected to be commissioned in Q1 FY27, with N-Methyl Morpholine (NMM) and Acetonitrile (ACN) plants following in FY27 and Q2 FY27, respectively. The Balaji Specialty Chemicals expansion, a phased INR 750 crore investment, will see Unit-I commissioned in H1 FY27 and Unit-II (for HCN, NaCN, EDTA) in Q4 FY27, significantly enhancing the specialty chemicals portfolio.

    04

    Operational Challenges and Raw Material Volatility

    The company faced operational challenges, including a brief production impact in March 2026 due to geopolitical events, which was managed through prudent inventory planning. Raw material prices, such as Monoethanolamine, have seen increases of up to 3 times normal levels. Management highlighted the need for constant vigilance in procurement to maintain margins amidst this volatility.

    05

    Volume Growth and Margin Outlook

    Management guided for a minimum 25-30% volume growth by the end of 2027 and aims to sustain EBITDA margins between 22-23% on total sales. For the current financial year, a consolidated volume growth of 10-15% is anticipated. DME utilization is projected to reach 30-40% in the current FY, increasing to 50-60% by year-end and 80-90% in coming years, despite initial teething problems for new products.

    06

    DME Market Opportunity and Customer Strategy

    The DME project targets the Aerosol industry and commercial establishments as a replacement for LPG, addressing India's significant LPG import dependency. The company has secured manufacturing approval for DME, with transportation approval pending. Balaji Amines is actively engaging potential customers, providing 500kg cylinders for testing, with bulk orders expected post-testing and receipt of transport permission.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.